# Sativa Wellness Group a true seed to consumer company (Interview)

- Link: https://www.directorstalkinterviews.com/sativa-wellness-group-a-true-seed-to-consumer-company-interview/412861974
- Published: 2020-10-01T07:00:00+01:00
- Author: Giles Arbor

**Sativa Wellness Group plc** (TSX / [AQSE:SWEL](https://www.directorstalkinterviews.com/company/goodbody-health/gdby.cn))
CEO Henry Lees-Buckley joins DirectorsTalk in this video interview to discuss the
merger of Sativa Group and StillCanna for form Sativa Wellness Group, a true seed
to consumer company. Henry explains what the new combined company looks like now,
how with the UK FSA Novel Foods process being implemented shortly this will affect
the company, traction its Goodbody brand is gaining and capabilities to white or
private label products and sell raw CBD ingredients.

Sativa Wellness, has announced that trading of its shares consisting of 302,592,941
Common Shares of no par value will commence trading at 8.00 a.m. today on the AQSE
Growth Market, with ISIN number CA80403E1043.

The Company will be dual-listed on both the Canadian Securities Exchange and the
AQSE growth Market. The Company also expects to be quoted on the over-the-counter(
the “OTC”) market in the United States and the Frankfurt Stock Exchange (the “FSE”)
shortly.

On 18 August 2020, Sativa Group plc announced that its shareholders had voted in
favour of a special resolution to approve the implementation of a Court-sanctioned
scheme of arrangement under Part 26 of the Companies Act for the merger with Stillcanna
Inc. The approved Scheme of Arrangement, became effective on 24 September 2020, 
and on 30 September 2020 trading of the combined entity, Sativa Wellness, on the
Canadian Securities Exchange, commenced under the same ticker “SWEL”.

Detailed information on the company can be found in both the Scheme of Arrangement
circular dated 22 July 2020 and the Stillcanna Management Information Circular dated
28 July 2020.

Sativa is focused on developing consumer products under the core “Goodbody” brand.
The Goodbody brands are available online and in a growing number of retailers across
the UK, all with the commitment of  “CBD you can Trust”. The plan is to extend the
Goodbody brands and product ranges into new markets throughout continental Europe.

Goodbody Botanicals offers a wide range of CBD products including gels, balms, capsules,
tinctures, gummies and more. The Goodbody Botanicals brand is available at the “
goodbodystore.com” and in hundreds of pharmacies and leading retailers across the
UK, such as WH Smith.

The Goodbody Wellness brand is focused on delivering premium products such as its
signature “Orange and Lemon flavored CBD with Vitamin D”. This brand is also available
online at the “goodbodystore.com” and is targeting health and beauty markets as 
well as high end retailers.

We continue to expand our product offerings in alignment with consumer demand, building
the range of products on offer. Additional Goodbody product lines such as Goodbody
sanitizer and Goodbody Hemp have also been launched and compliment the core CBD 
product offerings.

As a fully vertically-integrated company, Sativa not only manufactures its own core
products but also offers white label private manufacturing and branding services
for customers in the UK and Europe. The Company not only supplies the raw CBD isolate
and distillate ingredients, but also provides the formulation, bottling and testing
services to other CBD companies across Europe.

**Cultivation and Extraction Capabilities**

Sativa’s primary agricultural, cultivation and extraction business is based in Poland,
and is called Olimax. Olimax is responsible for the Company’s agricultural initiatives
including biomass partnerships throughout Europe. It is responsible for the operation
of the Company’s state of the art ethanol extraction facility in Poland providing
high quality CBD products to meet internal needs and importantly providing the key
ingredients to third party customers. The Olimax extraction facility is designed
to process over 400,000 kilos of CBD rich hemp biomass annually. The Olimax facility
produces both THC free CBD isolate and distillate for the global marketplace and
is fully operational and in production today.

Additionally, a wholly owned subsidiary, Borganic Consulting Inc., recently built
a modern extraction facility in Romania with a joint venture partner Dragonfly Biosciences
of London (“Dragonfly”).  The facility is now fully licensed and is capable of processing
over 400,000 kilos of CBD rich biomass annually. Borganic served notice of termination
of its joint venture with Dragonfly on August 17, 2020 as a result of a contract
dispute with Dragonfly.  The Company anticipates the issues will be resolved over
the coming months and will provide a further update once available.

**Testing Laboratories**

PhytoVista Laboratories (“**PVL**“) is Sativa’s independent analytical hemp and 
CBD testing facility. PVL provides laboratory support to retailers, distributors
and manufacturers by expertly testing the cannabinoid levels of the hemp and CBD
products. PVL is one of the UK’s most trusted laboratories operating to GLP (Good
Laboratory Practice) and ISO 17025 standards, with the aim of being fully ISO accredited
in 2020. 90% of the revenue of this laboratory is generated by external customers
with the balance from internal product testing.

The Olimax facility in Poland also has a modern laboratory with state-of-the-art
equipment and trained scientists. This laboratory is currently used for internal
product testing, but it is envisaged that this would also become an external customer
focused laboratory alongside the UK PhytoVista team.

**General**

In addition to the commercial operating activities, a wholly owned subsidiary “Sativa
Cultivation and Extraction Ltd” holds a Controlled Drug License for the cultivation,
production and possession of high THC content cannabis in the UK for medical research
as part of the Company’s partnership agreement with King’s College London to research
the impact of cannabinoids on inflammation and respiratory conditions. 

The new group is led by Henry Lees-Buckley, as Chief Executive Officer and Director.
Mr. Lees-Buckley is a seasoned corporate executive with extensive experience leading
companies in the private and public markets. Mr. Lees-Buckley was previously the
CEO of Uni-Select, a Canadian TSX quoted company with operations in the UK, Canada
and the USA. Prior to Uni-Select, Mr. Lees-Buckley was a senior global executive
and officer of W.W. Grainger a 15 billion dollar Fortune 500 company. Mr. Lees-Buckley
is currently a non-Executive director of Building Materials Corp (NASDAQ:BMCH) a
company with annual sales of USD3.8 billion. Henry holds an MBA from Queens University
in Kingston Ontario and has functioned as a senior executive in multiple global 
corporations.

Jason Dassault, the Company’s previous CEO, will remain with the Company going forward
as a director. Mr. Dussault will lead the Company’s investor relations and marketing
activities.

The Company is strictly focused on the European market and the primary offices are
located at:

The Blue Building, Stubbs Lane, Beckington, Somerset UK, BA11 6TE 

01373 486595

The Company’s investor relations and marketing office is in Vancouver, British Columbia.

Share on: